Filter

Refine by collections

  • 100 years of Insulin and Glucagon (3)

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 3 of 3 items for :

  • neuroendocrine carcinoma x
  • 100 years of Insulin and Glucagon x
  • Refine by access: All content x
Clear All
Krystallenia I Alexandraki Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed Close
,
Gregory A Kaltsas Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed Close
, and
Simona Grozinsky-Glasberg Department of Endocrinology and Metabolism, Neuroendocrine Tumor Unit, ENETS Center of Excellence, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed Close

-differentiated neuroendocrine carcinoma (NEC), either functioning or nonfunctioning and the combination cisplatin/etoposide is the most popular ( Baudin et al. 2013 ). Overall, 5-fluorouracil (5-FU), doxorubicin, and streptozotocin have been commonly used in the treatment of

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0020
Volume/Issue:
Volume 30: Issue 9
Free access
Alaa Sada Department of Surgery, Division of Endocrinology, Division of Gastroenterology and Hepatology, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Alaa Sada in
Google Scholar
PubMed Close
,
Travis J McKenzie Department of Surgery, Division of Endocrinology, Division of Gastroenterology and Hepatology, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Travis J McKenzie in
Google Scholar
PubMed Close
,
Adrian Vella Department of Surgery, Division of Endocrinology, Division of Gastroenterology and Hepatology, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Adrian Vella in
Google Scholar
PubMed Close
,
Michael J Levy Department of Surgery, Division of Endocrinology, Division of Gastroenterology and Hepatology, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Michael J Levy in
Google Scholar
PubMed Close
, and
Thorvardur R Halfdanarson Department of Surgery, Division of Endocrinology, Division of Gastroenterology and Hepatology, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed Close

Introduction In 1926, Dr William J Mayo operated on a patient with hypoglycemia induced by metastatic pancreatic neuroendocrine tumor (pNET) which led to the first description of insulinoma ( Wilder et al. 1927 ). Although the first

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-22-0362
Volume/Issue:
Volume 30: Issue 6
Free access
Wouter W de Herder Department of Internal Medicine, Sector of Endocrinology, Erasmus MC & Erasmus MC Cancer Institute, ENETS Center of Excellence, Rotterdam, the Netherlands

Search for other papers by Wouter W de Herder in
Google Scholar
PubMed Close
and
Günter Klöppel Department of Pathology, Technical University Munich, Munich, Germany

Search for other papers by Günter Klöppel in
Google Scholar
PubMed Close

two hormones. This review is a sequel to the discovery of insulin and glucagon and introduces the history of this fascinating group of neuroendocrine neoplasms and hyperplasias of the pancreas. Pancreatic islets Pancreatic islet cells were

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0046
Volume/Issue:
Volume 30: Issue 9
Free access